Clinical trialNCT05592626RecruitingPhase 1/PHASE2Interventional

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

SponsorMarengo Therapeutics, Inc.Enrollment366Abdominal NeoplasmAdvanced Solid TumorsCarcinomaColorectal CancerEpstein-Barr Virus InfectionsGenital Neoplasm, Female+8 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Lillian Siu, MD
Recruiting

France

Institute Gustave Roussy
Villejuif, France
Aurelien Marabelle, MD
Recruiting

Spain

Vall D'Hebron Institute of Oncology
Barcelona, Catalonia, Spain
Elena Garralda, MD
Recruiting
Hospital Universitario Quirónsalud Madrid
Madrid, Spain, Spain
Valentina Boni, MD
Recruiting
Start Madrid Fjd
Madrid, Spain
Manuel Pedregal, MD
Recruiting
Instituto de Investigacion Sanitaria, Incliva
Valencia, Spain
Susana Roselló, MD
Recruiting

United States

Uc Davis Comprehensive Cancer Center
Sacramento, California, United States
Active, not recruiting
Adventhealth Celebration
Celebration, Florida, United States
Guru Sonpavde, MD
Recruiting
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Active, not recruiting
the University of Kansas Cancer Center
Kansas City, Kansas, United States
Weijing Sun, MD
Recruiting
National Institutes of Health
Bethesda, Maryland, United States
James Gulley, MD, PhD
Recruiting
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Ryan Sullivan, MD
Recruiting
Karmanos Cancer Institute
Detroit, Michigan, United States
Wasif Saif, MD
Recruiting
the Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Asrar Alahmadi, MD
Recruiting
Sarah Cannon Research Institute Oncology Partners (scri-Nashville)
Nashville, Tennessee, United States
Meredith Pelster, MD
Recruiting
the University of Texas, Md Anderson Cancer Center
Houston, Texas, United States
Pia Morelli, MD, PhD
Recruiting
Ut Health Mays Cancer Center
San Antonio, Texas, United States
Sukeshi Patel Arora, MD
Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Active, not recruiting
University of Wisconsin- Madison
Madison, Wisconsin, United States
Vincent Ma, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

STAR0602 →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 4 Jan 2023
Primary completion: 30 Sept 2027
Completion: 30 Sept 2027
Last update posted: 11 Aug 2026
Registered enrollment: 366
Registry id: NCT05592626

Cross-registrations

EU-CTR / CTIS (EudraCT)2023-505334-10-01

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.